How are energy investors positioned?
SAN FRANCISCO - Bruker Corporation (BRKR), a $6.13 billion scientific instruments manufacturer with a robust 50% gross profit margin and 13.56% revenue growth in the last twelve months, has completed the first customer installation of its innovative dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer at the University of California San Francisco (UCSF). According to InvestingPro analysis, the company is expected to maintain its growth trajectory, with analysts projecting continued profitability this year. This technology is expected to significantly advance hyperpolarized MRI in preclinical cancer research by enhancing the sensitivity of Nuclear Magnetic Resonance (NMR) and Magnetic Resonance Imaging (MRI).
Dynamic Nuclear Polarization is a method that increases the sensitivity of NMR and MRI by transferring polarization from electron spins to nuclear spins. The d-DNP technology introduced by Bruker operates at temperatures below 1.4 Kelvin within a 7 Tesla polarizer magnet. It uses proprietary active cross-polarization technology to achieve over 10,000-fold sensitivity gains, allowing for real-time observation of low-abundance nuclei like 13C in solution samples.
Hyperpolarized MRI, utilizing d-DNP, is especially useful for in vivo studies of 13C-labelled metabolites, enabling researchers to observe metabolic processes as they occur. This can distinguish between healthy and diseased tissues, aiding in the diagnosis of conditions such as cancer and cardiac health, and in assessing treatment responses.
The new Bruker d-DNP Polarizer enables scientists to conduct experiments that were previously unfeasible, accelerating research in chemical and metabolic analysis. The patented cross polarization technology provides 5-10 times faster polarization compared to traditional d-DNP methods, which is crucial for rapid data acquisition in dynamic biological systems.
UCSF researchers have praised the new system for its potential to improve diagnostics for cancers and metabolic conditions. Professor Renuka Sriram of the preclinical Hyperpolarized Magnetic Resonance Imaging group at UCSF stated that the faster cross-polarization-based d-DNP technology and automated system will significantly enhance their research capabilities.
Dr. James Kempf, Senior Manager DNP & Hyperpolarization at Bruker BioSpin, emphasized Bruker’s commitment to driving innovation in hyperpolarization and the importance of their partnership with UCSF in developing technologies that may transform healthcare.
The collaboration between Bruker and UCSF is expected to lead to further advancements in hyperpolarized MRI, with additional d-DNP customer installations planned in Europe and the US. The ongoing partnership aims to validate the d-DNP technology in oncology applications, demonstrating the value of the higher-throughput cross-polarization d-DNP approach. With the stock currently trading near its 52-week low, InvestingPro data suggests Bruker may be undervalued, presenting an interesting opportunity for investors following healthcare technology innovations. For detailed analysis of Bruker’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
This development is based on a press release statement from Bruker Corporation, a company focused on providing high-performance scientific instruments and analytical and diagnostic solutions. The company maintains a healthy current ratio of 1.6 and demonstrates strong cash flows sufficient to cover interest payments, indicating solid financial stability as it continues to innovate in the medical technology sector.
In other recent news, Bruker Corporation reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $0.76, compared to the forecast of $0.74. The company’s revenue also exceeded projections, reaching $979.6 million against the expected $962.38 million, marking a 14.6% year-over-year increase. Bruker continues to focus on strategic acquisitions and innovation, with guidance for 2025 indicating expected revenue growth and margin expansion.
Additionally, Bruker has launched the X4 POSEIDON, a new benchtop 3D X-ray microscope system, designed to provide high-resolution imaging capabilities. The company also announced advancements in proteomics technology, including the introduction of the Athena Ion Processor on the timsTOF Ultra 2 system, expected to enhance protein group identification. These technological developments were showcased at the 21st Annual US HUPO Conference.
In another development, Bruker appointed Laura Francis as an independent director to its board, with plans for her to join the Audit Committee as a financial expert. Her extensive experience in the medtech and life science tools industries is expected to support Bruker’s growth and strategic execution. These recent developments reflect Bruker’s ongoing commitment to innovation and leadership in its field.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.